Illumina
    Print Page  Close Window
Illumina Files Patent Infringement Suit Against BGI in Denmark

SAN DIEGO--(BUSINESS WIRE)--May 15, 2019-- Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark.

“As we have previously stated, Illumina will continue to vigorously protect our patented technology and file patent suits where appropriate when our patents are infringed,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.

The complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 3 002 289 B1. This patent covers Illumina’s proprietary sequencing-by-synthesis chemistry. The complaint also alleges that BGI’s use of the MGISEQ mark infringes Illumina’s registered EU Trademark No. 8972127 for the MISEQ name.

Earlier this year, Illumina filed a patent infringement suit against BGI Group’s subsidiary, Latvia MGI Tech SIA, in the Düsseldorf Regional Court in Germany. That complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 1 530 578 B1.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
+1-858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com
or
Media – Europe:
Karen Birmingham
+44(0) 7500105665
kbirmingham@illumina.com